ACADIA Pharmaceuticals Inc.
ACAD
Ранг среди акций
#4651
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Цена акции
$18.95
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$3.26B
Изменение (1 день)
-3.86%
Изменение (1 год)
-9.29%
Страна
US
Торговля ACADIA Pharmaceuticals Inc. (ACAD)
Категория
Healthcare
Операционная маржа для ACADIA Pharmaceuticals Inc. (ACAD)
Операционная маржа на October 2026 TTM: 7.59%
Согласно последним финансовым отчетам и цене акций ACADIA Pharmaceuticals Inc., текущая операционная маржа (TTM) составляет 7.59%. В конце 2023 она составила -10.10%.
История операционной маржи ACADIA Pharmaceuticals Inc. с 2000 по 2026
Операционная маржа на конец каждого года
| Год | Операционная маржа | Изменить |
|---|---|---|
| 2026 (TTM) | 7.59% | -68.51% |
| 2024 | 24.10% | -338.61% |
| 2023 | -10.10% | -76.64% |
| 2022 | -43.23% | 22.81% |
| 2021 | -35.20% | -45.74% |
| 2020 | -64.87% | -10.78% |
| 2019 | -72.71% | -34.23% |
| 2018 | -110.56% | -52.77% |
| 2017 | -234.11% | -85.13% |
| 2016 | -1,574.14% | -99.42% |
| 2015 | -269,855.74% | 247.34% |
| 2014 | -77,691.67% | 2,222.82% |
| 2013 | -3,344.72% | 685.81% |
| 2012 | -425.64% | -61.50% |
| 2011 | -1,105.56% | -3,186.43% |
| 2010 | 35.82% | -105.04% |
| 2009 | -710.55% | -83.13% |
| 2008 | -4,212.45% | 407.95% |
| 2007 | -829.31% | 37.50% |
| 2006 | -603.15% | 84.56% |
| 2005 | -326.81% | -42.34% |
| 2004 | -566.76% | 204.35% |
| 2003 | -186.22% | -7.44% |
| 2002 | -201.19% | -51.10% |
| 2001 | -411.39% | 57.42% |
| 2000 | -261.34% | 0.00% |
Операционная маржа для аналогичных компаний или конкурентов
| Компания | Операционная маржа | Разница в операционной марже | Страна |
|---|---|---|---|
| 38.59% | -94.92% |
US
|
|
| -149.01% | -119.63% |
US
|
|
| 25.57% | -96.63% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -96.20% |
NL
|
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.